anti-gpc3-car t-lymphocytes tak-102
Generic: Anti-GPC3-CAR T-lymphocytes TAK-102
anti-gpc3-car t-lymphocytes tak-102: 1 clinical trial tracked.
anti-gpc3-car t-lymphocytes tak-102 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-gpc3-car t-lymphocytes tak-102, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-102 in Adult Patients With GPC3-Expressing Previously Treated Solid Tumors
Primary endpoint: Number of Participants with First Cycle Dose-Limiting Toxicities (DLTs)
Interventionalopen12 targetStarted 2020-07Completion 2025-053 sites · JapanTakeda